CRVS — Corvus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $895.89m
- $680.66m
Brief: Corvus Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Corvus Pharma slips after launching $150 mln equity offering
Brief: Corvus Pharmaceuticals Announces Positive Early-Stage Soquelitinib Data For Atopic Dermatitis
Brief: Corvus To Announce Results From Cohort 4 Of Placebo-Controlled Phase 1 Clinical Trial
Corvus Pharma Q3 net loss narrows; R&D expenses rise
Brief: Corvus Pharmaceuticals Q3 EPS USD -0.12
Brief: Corvus Pharmaceuticals Appoints David Moore To Board Of Directors
Corvus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Corvus Pharmaceuticals Q2 EPS USD -0.1
Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib
Brief: Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
Corvus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors
Corvus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview